A First-in-Human, Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose-Optimization, and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PARP1 Selective Inhibitor, IMP1734, in Patients with Advanced Solid Tumors

Sponsor:

Eikon Therapeutics

Sponsor Study ID:

EIK1003-001 (IMP1734-101)

CTO #:

103989

NCT Number:

NCT06253130

Phase:

I/II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Breast; Ovary; Prostate

Study Objectives:

To evaluate the safety and tolerability of IMP1734. To determine the MTD (or MAD) and RDE. To characterize the plasma PK profile of single and multiple doses of IMP1734. To assess preliminary anti-tumor activity of IMP1734.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)